Caprock Group’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-854
Closed -$12.3K 681
2022
Q4
$12.3K Hold
854
﹤0.01% 553
2022
Q3
$20K Hold
854
﹤0.01% 566
2022
Q2
$17K Hold
854
﹤0.01% 548
2022
Q1
$31K Hold
854
﹤0.01% 600
2021
Q4
$38K Buy
+854
New +$51.2K ﹤0.01% 578

Other funds holding ASLN

Caprock Group's ASLN Position: Q1 2023 in Review

Caprock Group sold out of ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) in Q1 2023, closing a stake of 854 shares — an estimated $12.3K sold.

Caprock Group first reported a position in ASLN in Q4 2021 and held it in 5 quarters. The position peaked at $38K in Q4 2021. 16 funds tracked by Wall St. Rank hold ASLN as of Q1 2023.

  • Caprock Group reported no remaining ASLAN Pharmaceuticals Limited American Depositary Shares position as of Q1 2023 after selling out during the quarter.
  • Caprock Group sold 854 ASLAN Pharmaceuticals Limited American Depositary Shares shares in Q1 2023, an estimated $12.3K.
  • Caprock Group first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q4 2021 and held it in 5 quarters.
  • Caprock Group's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $38K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q1 2023.

Based on Caprock Group's 13F filing for Q1 2023, filed 26 Apr 2023.